About

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Visit our Heart Failure Management Hub to discover a range of educational content to facilitate the use of SGLT-2 inhibitors and other guideline directed medical therapies as foundational treatment for HF.

Articles

Ischemic Complications of Pregnancy: Who is at Risk?

Citation:

US Cardiology Review 2016;10(1):14–20

Promising New Therapies in Heart Failure: Ivabradine and the Neprilysin Inhibitors

Citation:

US Cardiology Review 2016;10(1):8–13

Treatment of Chronic Heart Failure

Citation:

US Cardiology 2006;3(1):1–5

The Role of Aldosterone Blockade in Patients with Heart Failure Due to Systolic Left Ventricular Dysfunction

Citation:

US Cardiology 2004;1(1):1–6